Chronic viral hepatitis B
Conditions
Interventions
Group of patients with clinically cured CHB (HBsAg< 0.05 IU/mL):None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Participants must meet all of the following inclusion criteria to be enrolled in this study. 1. Aged between 18 (inclusive) and 65 (inclusive) years; 2. Patients with clinical cure of CHB after treatment with NAs or PEG-IFN: 1) Disappearance of HBsAg (< 0.05 IU/mL) (after at least 2 tests, 6 months or more apart); 2) HBV DNA negative (high precision, < 20 IU/mL); 3) HBeAg negative; 3. No contraindications to liver puncture, intention to liver puncture and understanding to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects with any of the following conditions are not eligible to participate in this study; 2. The subjects had a history of hepatic decompensation, or had ascites, gastrointestinal bleeding, hepatic encephalopathy, or spontaneous peritonitis; 3. The subjects had been diagnosed with hepatocellular carcinoma or had been indicated by relevant examinations, such as suspected HCC nodules on imaging, or obvious abnormalities of AFP and PIVKA-II; 4. Confirmed or suspected malignant tumors other than liver cancer; 5. Combined with HCV or HIV infection; 6. Subjects need to take immunosuppressants or glucocorticoids; 7. Patients with serious and important organ diseases other than hepatitis B, such as cardiovascular, pulmonary, renal, and brain diseases; 8. Patients with autoimmune diseases, psychosis, diabetes, and abnormal thyroid function. 9. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cccDNA;HBV DNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBV RNA;HBcrAg;HBsAg; | — |
Countries
China
Contacts
Public ContactHong Tang
West China Hospital of Sichuan University
Outcome results
None listed